New hepatitis b drug shows early promise in small study

NCT ID NCT07515209

Completed Disease control Sponsor: Huahui Health Source: ClinicalTrials.gov ↗

First seen Apr 11, 2026 · Last updated Apr 24, 2026 · Updated 2 times

Summary

This early-stage study tested a new drug called HH-006 in 36 adults with untreated chronic hepatitis B. The main goal was to check safety and how the body processes the drug, while also looking at its ability to fight the virus. Participants received either the drug or a placebo over several weeks and were monitored for 24 weeks. Results will help decide if larger studies are warranted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

NanFang Hospital of Southern Medical University

Guangzhou, Guangdong, 510000, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510000, China
The Eighth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510000, China

Conditions

Explore the condition pages connected to this study.

CHRONIC HEPATITIS B VIRUS INFECTION